This opening session brings together leading Chief IP Counsel from both innovative and generic companies to share their insights and strategies for navigating the complexities of pharmaceutical and biotech IP in the European context. Points of discussion will cover:

Innovator Perspectives:

• Emphasizing the role of patents in driving innovation within the European pharmaceutical landscape
• Key strategies for building a robust patent portfolio in a changing European IP environment
• Navigating patent listing and protection strategies in line with European regulations
• Anticipating litigation under the new UPC regime, including the strategic timing for patent defense

Generic Perspectives:

• Identifying viable patents for challenge under European laws and the UPC framework
• Criteria for targeting specific patents for opposition or invalidation
• Approaches to assessing patent invalidity and non-infringement in the European context

Considerations for Both Sides:

• Decision-making on when to engage outside counsel versus handling matters in-house in the European context
• Addressing complex legal challenges and anticipating future trends in European pharma IP law